Guidelines for Concurrent Use of Auvelity (dextromethorphan‑bupropion) with SSRIs
Pharmacology and Serotonin‑Syndrome Risk
- Dextromethorphan in Auvelity functions as an NMDA‑receptor antagonist and sigma‑1‑receptor agonist, but it also inhibits serotonin reuptake, contributing to serotonin‑syndrome risk when combined with SSRIs【1】【2】.
Clinical Presentation of Serotonin Syndrome
- The syndrome can manifest with mental‑status changes (confusion, agitation, anxiety), neuromuscular hyperactivity (tremor, clonus, hyperreflexia, rigidity), autonomic hyperactivity (hypertension, tachycardia, diaphoresis, gastrointestinal upset), and may progress to fever, seizures, arrhythmias, or loss of consciousness; these findings are documented in multiple case series【3】【4】【5】【6】【7】.
- Symptoms typically emerge within the first 24–48 hours after initiating or adjusting two serotonergic agents【3】【4】【5】【6】【8】.
Pre‑initiation Screening and Contraindications
- Prior to adding Auvelity to an SSRI, clinicians should screen for concurrent use of over‑the‑counter dextromethorphan‑containing products (e.g., cough/cold medicines)【3】【4】【5】.
- Use of monoamine‑oxidase inhibitors (MAOIs) is an absolute contraindication; a minimum 14‑day washout period is required before starting Auvelity【3】【4】【5】.
Monitoring Protocol (American Academy of Child and Adolescent Psychiatry)
- Initiate the added serotonergic medication at a low dose and titrate upward slowly【3】【4】【5】【6】【8】.
- Conduct intensive monitoring for serotonin‑syndrome signs during the first 24–48 hours after any dose change, with continued vigilance thereafter【3】【4】【5】【6】【8】.
- When Auvelity is added to an existing SSRI regimen, maintain heightened observation for the initial 48 hours【3】.
CYP2D6 Interaction Considerations
- Bupropion is a strong CYP2D6 inhibitor; this raises plasma concentrations of dextromethorphan and of SSRIs that are CYP2D6 substrates, potentially amplifying serotonin‑syndrome risk【9】.
- SSRIs with notable CYP2D6 metabolism include fluoxetine, paroxetine, and sertraline【4】【7】【10】.
Safer SSRI Options
- Citalopram and escitalopram exhibit minimal CYP450 inhibition and therefore present a lower interaction potential when combined with Auvelity【4】【7】【10】.
Management of Established Serotonin Syndrome
- Immediate discontinuation of both Auvelity and the SSRI is recommended【ignore ref】.
- Hospital admission for supportive care and continuous cardiac monitoring is advised, based on case series evidence【3】【4】【5】.
- Consideration of serotonin antagonists (e.g., cyproheptadine) and benzodiazepines may be appropriate, though specific efficacy data are limited【ignore ref】.
Common Pitfalls to Avoid
- Do not assume the combination is prohibited; the FDA label warns of risk but does not forbid concurrent use【ignore ref】.
- Over‑the‑counter dextromethorphan products can add to serotonergic load and should not be overlooked【3】【4】【5】.
- Early serotonin‑syndrome symptoms (confusion, agitation) must not be misinterpreted as worsening depression【ignore ref】.
- Combining with MAOIs is prohibited and requires a 14‑day washout【3】【4】【5】.
Clinical Algorithm for Concurrent Use
| Step | Action | Evidence |
|---|---|---|
| 1 | Confirm no MAOI use within the past 14 days | — |
| 2 | Screen for other dextromethorphan or bupropion products | — |
| 3 | Prefer citalopram or escitalopram if a new SSRI is needed (lower CYP2D6 interaction) | 【4】【7】【10】 |
| 4 | Educate the patient on recognizing serotonin‑syndrome signs | — |
| 5 | Initiate Auvelity at the standard dose (one tablet twice daily, ≥8 h apart) | — |
| 6 | Monitor intensively for the first 24–48 h, then continue regular follow‑up | 【3】【4】【5】 |
| 7 | If serotonin‑syndrome symptoms appear, stop both agents immediately and seek emergency care | — |
Strength of evidence: Most recommendations are based on expert consensus and case‑series data (Level C).